Поражение печени при кори

Objective: to determine the incidence of liver damage with measles, the specificity of these changes, to identify risk groups, to assess the dynamics of the development of hyperfermentemia in various stages of the disease.Materials and methods: a retrospective cohort study of medical records of patients hospitalized with measles (n = 101), divided into 4 groups: children (n = 23), men (n = 32), women (n = 24) and pregnant women (n = 22). Patients with laboratory-confirmed influenza (n = 61) were taken as a comparison group. The analysis of the frequency of detecting changes in biochemical parameters, average values, standard error and confidence intervals.Results: An increase in ALT in measles patients was observed in 56 (55.4%), above 5 norms – in 15 patients (14.8%), an increase in AST was detected in 80 (79.2%) patients, above 5 norms – in 10 (9.9%). These changes are specific for measles, which was established by comparing the indicators of patients with measles and influenza. The greatest frequency and severity of the observed changes was observed in men. Determination of bilirubin concentration was carried out in 95 patients. An increase in total bilirubin above 20 μmol / L was observed in 10 (10.5%), direct above 5 μmol / L – in 13 (13.6%) patients.Conclusion: given the frequency of occurrence of the identified changes, it is advisable to conduct a biochemical blood test for measles patients. Therapeutic tactics should be determined taking into account the possible development of hepatitis with measles. Цель: определение частоты развития гепатита при кори, специфичности данных изменений, определение групп риска, оценка динамики развития гиперферментемии в различных стадиях заболевания.Материалы и методы: ретроспективное когортное исследование медицинских карт пациентов, госпитализированных с диагнозом «Корь» (n=101), с разбивкой на 4 группы: дети (n=23), мужчины (n=32), женщины (n=24) и беременные (n=22). В качестве группы сравнения взяты больные с лабораторно подтвержденным гриппом (n=61). Проведен анализ частоты выявления изменений в биохимических показателях, средних величин, стандартной ошибки и доверительных интервалов.Результаты: повышение АЛТ у больных корью наблюдалось у 56 (55,4%), выше 5 норм – у 15 человек (14,8%), повышение АСТ выявлено у 80 (79,2%) больных, выше 5 норм – у 10 (9,9%). Данные изменения специфичны для кори, что было установлено при сравнении показателей больных корью и гриппом. Наибольшая частота и выраженность наблюдаемых изменений отмечалась у мужчин. Определение концентрации билирубина было проведено у 95 больных. Повышение общего билирубина выше 20 мкмоль/л отмечалось у 10 (10,5%), прямого выше 5 мкмоль/л – у 13 (13,6%) пациентов.Заключение: учитывая частоту встречаемости выявленных изменений, целесообразно проводить биохимический анализ крови больным корью. Лечебная тактика должна определяться с учетом возможного развития гепатита при кори.

Эффективность и безопасность применения цепэгинтерферона альфа 2b в составе двойной (цепэгинтерферон альфа 2b и рибавирин) и тройной (симепревир, цепэгинтерферон альфа 2b и рибавирин) схемы противовирусной терапии у пациентов с хроническим гепатитом С. Опыт реальной клинической практики

The objective. To evaluate the efficacy, safety and tolerability of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients in everyday clinical practice of the Hepatology Center in Clinical Infectious Diseases Hospital in Moscow.Materials and methods. From 2013 to 2015 a total of 289 patients with chronic hepatitis C received antiviral therapy with cepeginterferon alfa 2b. 267 patients received combination of cepeginterferon alfa 2b and ribavirin. 22 patients received triple antiviral therapy with simeprevir, cepeginterferon alfa 2b and ribavirin. Treatment efficacy was assessed by the rate of sustained virologic response on 12/24 week after completion of antiviral therapy (SVR 12/24). In safety analysis all 289 patients were included. All cases of deterioration of the patient’s condition and laboratory abnormalities were registered throughout the treatment period and follow up.Results. 267 patients (74,5%, n=199, with 2/3 genotype, 25,5%, n = 68, with 1 genotype) received cepeginterferon alfa 2b 1,5 µg/kg/week and ribavirin 800-1400 daily (weight based). 22 patients with genotype 1 (the majority of them had advanced fibrosis (F3-F4) underwent triple therapy with simeprevir 150 mg once daily in combination with cepeginterferon alfa 2b 1,5 µg/kg/week and ribavirin 800-1400 mg daily (weight based) for 12 weeks, followed by cepeginterferon alfa 2b/ ribavirin therapy for 12-36 weeks. SVR was observed in 85,6% (n=113) of genotype 2/3 infected patients and in 64,6% (n=31) of genotype 1 infected patients. Among patients with mild or moderate fibrosis SVR rate was 90,7% in genotype 2/3 patients and 75% in genotype 1 patients. 21 patient completed the course of triple therapy. SVR was observed in 71,4% (n=15) of patients. Registered adverse reactions were common for interferon/ribavirin based therapy. In most cases adverse events were moderate and matched grade 1-2 of CTCAE.Conclusion. The present experience confirms the efficacy and safety of double therapy including cepeginterferon alfa 2b and ribavirin in genotype 1 and 2/3 infected patients. The use of this regimen is reasonable in patients who don’t have negative predictive factors of response to interferon-based therapy. In patients with genotype 1 HCV and/or advanced fibrosis (F3-F4) adding of simeprevir to the cepeginterferon alfa/ribavirin combination reduces the duration of treatment, improves the efficacy, while maintaining a good safety profile.Цель: оценить эффективность, безопасность и переносимость применения цепэгинтерферона альфа 2b в составе двойной (цепэгинтерферон альфа 2b и рибавирин) и тройной (симепревир, цепэгинтерферон альфа 2b и рибавирин) схем противовирусной терапии у пациентов с хроническим гепатитом С в реальной клинической практике.Материалы и методы. C 2013 по 2015 г. в Центре по лечению хронических вирусных гепатитов Инфекционной клинической больницы № 1 г. Москвы 289 пациентов с хроническим гепатитом С получали противовирусную терапию (ПВТ) схемами, включавшими цепэгинтерферон альфа 2b. 267 пациентов получали цепэгинтерферон альфа 2b и рибавирин. 22 пациентам была назначена тройная схема ПВТ (симепревир, цепэгинтерферон альфа 2b и рибавирин). Эффективность лечения определялась частотой достижения вирусологического ответа через 12/24 недели после окончания терапии (УВО 12/24). В анализ безопасности включены все пациенты, получавшие цепэгинтерферон альфа 2b (n=289).Результаты. 267 пациентов (74,5% (n=199) пациентов – 2/3 генотип, 25,5% (n=68) пациентов – 1 генотип HCV) получали цепэгинтерферон альфа 2b 1,5 мкг/кг/ нед. и рибавирин 800–1400 мг/сут. 22 пациентам с 1 генотипом (у большинства из них имелся фиброз F3–F4) был назначен симепревир 150 мг/сут, цепэгинтерферон альфа 2b 1,5 мкг/кг/нед, рибавирин 800–1400 мг/сут в течение 12 недель, далее цепэгинтерферон альфа 2b и рибавирин в течение 12/36 недель.При применении двойной схемы ПВТ УВО достигли 85,6% (n=113) пациентов с 2/3 генотипом и 64,6% (n=31) пациентов с 1 генотипом HCV. Среди пациентов с фиброзом F1–F2 УВО зафиксирован у 90,7% пациентов с 2/3 генотипом HCV и у 75% с 1 генотипом HCV. Курс лечения тройной схемой терапии завершил 21 пациент, УВО достигли 71,4% (n=15) пациентов.Зафиксированные нежелательные явления были характерны для применявшихся режимов терапии. В большинстве случаев реакции были незначительно или умеренно выражены.Заключение. Опыт реальной клинической практики показал, что применение двойной схемы ПВТ (цепэгинтерферон альфа 2b и рибавирин) эффективно и безопасно у пациентов как с 1, так и со 2/3 генотипами HCV. Оправдано назначение такой терапии пациентам, не имеющим предикторов неблагоприятного ответа на лечение. Добавление к комбинации цепэгинтерферона альфа 2b и рибавирина симепревира позволяет повысить эффективность терапии и сократить ее длительность при сохранении хорошего профиля безопасности у пациентов с 1 генотипом HCV и более продвинутыми стадиями заболевания

Liver damage with measles

Objective: to determine the incidence of liver damage with measles, the specificity of these changes, to identify risk groups, to assess the dynamics of the development of hyperfermentemia in various stages of the disease.Materials and methods: a retrospective cohort study of medical records of patients hospitalized with measles (n = 101), divided into 4 groups: children (n = 23), men (n = 32), women (n = 24) and pregnant women (n = 22). Patients with laboratory-confirmed influenza (n = 61) were taken as a comparison group. The analysis of the frequency of detecting changes in biochemical parameters, average values, standard error and confidence intervals.Results: An increase in ALT in measles patients was observed in 56 (55.4%), above 5 norms – in 15 patients (14.8%), an increase in AST was detected in 80 (79.2%) patients, above 5 norms – in 10 (9.9%). These changes are specific for measles, which was established by comparing the indicators of patients with measles and influenza. The greatest frequency and severity of the observed changes was observed in men. Determination of bilirubin concentration was carried out in 95 patients. An increase in total bilirubin above 20 μmol / L was observed in 10 (10.5%), direct above 5 μmol / L – in 13 (13.6%) patients.Conclusion: given the frequency of occurrence of the identified changes, it is advisable to conduct a biochemical blood test for measles patients. Therapeutic tactics should be determined taking into account the possible development of hepatitis with measles

The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice

The objective. To evaluate the efficacy, safety and tolerability of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients in everyday clinical practice of the Hepatology Center in Clinical Infectious Diseases Hospital in Moscow.Materials and methods. From 2013 to 2015 a total of 289 patients with chronic hepatitis C received antiviral therapy with cepeginterferon alfa 2b. 267 patients received combination of cepeginterferon alfa 2b and ribavirin. 22 patients received triple antiviral therapy with simeprevir, cepeginterferon alfa 2b and ribavirin. Treatment efficacy was assessed by the rate of sustained virologic response on 12/24 week after completion of antiviral therapy (SVR 12/24). In safety analysis all 289 patients were included. All cases of deterioration of the patient’s condition and laboratory abnormalities were registered throughout the treatment period and follow up.Results. 267 patients (74,5%, n=199, with 2/3 genotype, 25,5%, n = 68, with 1 genotype) received cepeginterferon alfa 2b 1,5 µg/kg/week and ribavirin 800-1400 daily (weight based). 22 patients with genotype 1 (the majority of them had advanced fibrosis (F3-F4) underwent triple therapy with simeprevir 150 mg once daily in combination with cepeginterferon alfa 2b 1,5 µg/kg/week and ribavirin 800-1400 mg daily (weight based) for 12 weeks, followed by cepeginterferon alfa 2b/ ribavirin therapy for 12-36 weeks. SVR was observed in 85,6% (n=113) of genotype 2/3 infected patients and in 64,6% (n=31) of genotype 1 infected patients. Among patients with mild or moderate fibrosis SVR rate was 90,7% in genotype 2/3 patients and 75% in genotype 1 patients. 21 patient completed the course of triple therapy. SVR was observed in 71,4% (n=15) of patients. Registered adverse reactions were common for interferon/ribavirin based therapy. In most cases adverse events were moderate and matched grade 1-2 of CTCAE.Conclusion. The present experience confirms the efficacy and safety of double therapy including cepeginterferon alfa 2b and ribavirin in genotype 1 and 2/3 infected patients. The use of this regimen is reasonable in patients who don’t have negative predictive factors of response to interferon-based therapy. In patients with genotype 1 HCV and/or advanced fibrosis (F3-F4) adding of simeprevir to the cepeginterferon alfa/ribavirin combination reduces the duration of treatment, improves the efficacy, while maintaining a good safety profile